Medical Grand Rounds



Presented by CONTINUING N Yale School of Medicine, Department of Internal Medicine, Section of Digestive Diseases

The 50th Annual Samuel D. Kushlan Visiting Professorship



Nicholas J. Talley, MD, PhD

Pro Vice-Chancellor, Global Research, University of Newcastle (UON), Australia Director, Priority Research Centre, Digestive Health and Neurogastroenterology Senior Staff Specialist, John Hunter Hospital, Newcastle, Australia Editor-in-Chief, Medical Journal of Australia Professor of Medicine and Professor of Epidemiology, Mayo Clinic

Date: February 21, 2019 Time: 8:30-9:30am Location: Fitkin Auditorium

"Non-Celiac Gluten Sensitivity (NCGS) – A True Disease or Misdiagnosis?"

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION:

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

<u>TARGET AUDIENCE:</u> Attending physicians, house staff, fellows, medical students, PA's.

NEEDS ASSESSMENT:

The effective practice of medicine requires the ability to elicit and interpret the stories of patients. Clinicians need to have knowledge of the principles of narrative medicine, and their application to patient care.

LEARNING OBJECTIVES:

- 1. Understand the disease burden and associated comorbidities in the US and internationally
- 2. Review current knowledge of disease pathways in NCGS including the relevance of duodenal pathlogy
- 3. Critically evaluate management strategies including the risks and benefits of a gluten free diet in NCGS.

DESIGNATION STATEMENT:

The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)^M. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES:

Course Director: Vincent Quagliarello, MD - None Speaker: Nicholas J. Talley, MD, PhD- Grant / Research Support: Commonwealth Diagnostics (International) Inc (IBS) (ceased 2017); Prometheus USA (funding ceased – no current funding in 3 year cycle but study data being analysed); HVN National Science Challenge NZ (no financial support) Patents: Biomarkers of irritable bowel syndrome (#12735358.9 -1405/2710383 and (#12735358.9 -1405/2710384); Licensing Questionnaires (Mayo Clinic) Talley Bowel Disease Questionnaire, Mayo Dysphagia Questionnaire; Nestec European Patent Application No. 12735358.9; Singapore 'Provisional' Patent NTU Ref: TD/129/17 "Microbiota Modulation of BDNF Tissue Repair Pathway" Consultancies: Adelphi values (functional dyspepsia working group to develop a symptom based PRO instrument) 2017

Allergens PLC (GI Development Program) 2017; GI therapies (noninvasive device company, consultant and options) 2017; IM Health Sciences, USA 2017-2018; Napo Pharmaceutical 2017; Outpost Medicine 2017; Samsung Bioepis 2017; Synergy (IBS) 2017; Theravance (gastroparesis) 2017 Miscellaneous: Avant Foundation (judging of research grants) (2017-2019)

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.